Allogene Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $10.00M.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $3.19M.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $87.92M.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $595.70M.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $91.11M.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $595.73M, a 998.75% increase from fiscal 2019.
- Allogene Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $54.22M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-03-31 | $10.00M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $91.11M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $3.19M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $87.92M 10-Q · filed 2023-11-02 | |
| 2020-12-31 | $595.73M 10-K · filed 2021-02-25 | |
| 2020-06-30 | $595.70M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $14.85M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $54.22M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |